Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2018
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Marina Bacac, Sara Colombetti, Sylvia Herter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2021
Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity
Eva Sum, Moritz Rapp, Philipp Fröbel, et al.
Cancer Research Communications
|
June 12, 2026
Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor control
Patrick A A Weber, Mario Perro, Valeria G Nicolini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2016
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac, Tanja Fauti, Johannes Sam, et al.
The New England Journal of Medicine
|
November 6, 2009
Inflammatory bowel disease and mutations affecting the interleukin-10 receptor
Erik-Oliver Glocker, Daniel Kotlarz, Kaan Boztug, et al.
Nature
|
September 28, 2022
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8<sup>+</sup> T cells
Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto, et al.
Blood
|
May 16, 2023
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
Blandine Pouleau, Carole Estoppey, Perrine Suere, et al.
Nature Cancer
|
September 11, 2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret, et al.
Journal for Immunotherapy of Cancer
|
June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
Kristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
The Journal of Allergy and Clinical Immunology
|
February 18, 2010
Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome
Cristina Woellner, E Michael Gertz, Alejandro A Schäffer, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2018
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Marina Bacac, Sara Colombetti, Sylvia Herter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2021
Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity
Eva Sum, Moritz Rapp, Philipp Fröbel, et al.
Cancer Research Communications
|
June 12, 2026
Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor control
Patrick A A Weber, Mario Perro, Valeria G Nicolini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2016
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac, Tanja Fauti, Johannes Sam, et al.
The New England Journal of Medicine
|
November 6, 2009
Inflammatory bowel disease and mutations affecting the interleukin-10 receptor
Erik-Oliver Glocker, Daniel Kotlarz, Kaan Boztug, et al.
Nature
|
September 28, 2022
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8<sup>+</sup> T cells
Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto, et al.
Blood
|
May 16, 2023
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
Blandine Pouleau, Carole Estoppey, Perrine Suere, et al.
Nature Cancer
|
September 11, 2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret, et al.
Journal for Immunotherapy of Cancer
|
June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
Kristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
The Journal of Allergy and Clinical Immunology
|
February 18, 2010
Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome
Cristina Woellner, E Michael Gertz, Alejandro A Schäffer, et al.
Page
of 4